DbpA/B proteins of Borrelia burgdorferi & Lyme arthritis
Project Number5R03AR049383-02
Contact PI/Project LeaderPARVEEN, NIKHAT
Awardee OrganizationUNIV OF MASSACHUSETTS MED SCH WORCESTER
Description
Abstract Text
DESCRIPTION (provided by applicant): Lyme disease presents a unique clinical system to study cellular and molecular mecahnisms responsible for chronic inflammatory diseases. The disease, caused by the spirochete Borrelia burgdorfen, is the most prevalent arthropod borne disease in the United States. It is a multisystemic illness that affects skin, muscles, joints, heart and nervous system. If left untreated, chronic manifestations are frequenctly observed and Lyme arthritis is the most common symptom in North America. My Iong term qoal is to identify the virulence factors of B. burgdorferi involved in attachment to host cells and in colonization of various tissues, and characterize their role in the pathogenesis, diagnosis and prevention of chronic Lyme disease. Glycosaminoglycans (GAGs), ubiquitously expressed on the surface of all nucleated cells, are recognized by various Lyme spirochetes and several bacterial molecules are involved in this adherence. Decorin binding lipoproteins DbpA and DbpB of B. burgdorferi show affinity for heparin and dermatan sulfate GAGs in addition to the proteoglycan decorin. My hypothesis is that DbpA and DbpB contribute to the colonization of various tissues by B. burgdorferi binding to GAGs and decorin present on the host cells and trigger an inflammatory response in skin and joints causing erythema migrans and Lyme arthritis. The major question to be addressed in this study are: (1) Do DbpA and DbpB contribute to the GAGsmediated attachment of B. burgdorferi to host cells and to the inflammatory response in the joints of susceptible mice? (2) Does deletion of dbpA and dbpB genes affect attachment of B. burgdorferi to the host cells? (3) Are DbpA and DbpB lipoproteins essential virulence factors of B. burgdorferi that trigger Lyme arthritis? Si,qniflcance: Lyme arthritis exhibits several symptoms similar to those of rheumatoid arthritis. However, unlike rheumatoid arthritis, the causative agent is known in Lyme disease and hence, it is feasible to analyze the molecular mechanisms involved in this form of destructive arthritis. In addition, B. burgdorfer/ infected mouse exhibits symptoms similar to those of human Lyme disease, and hence, murine model provides an ideal system to analyze the mechanisms of Lyme borreliosis. This study will characterize the role of two spirochete lipoprotein adhesins in Lyme arthritis in the murine model.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
846
DUNS Number
603847393
UEI
MQE2JHHJW9Q8
Project Start Date
01-March-2003
Project End Date
28-February-2006
Budget Start Date
29-February-2004
Budget End Date
28-February-2005
Project Funding Information for 2004
Total Funding
$79,500
Direct Costs
$50,000
Indirect Costs
$29,500
Year
Funding IC
FY Total Cost by IC
2004
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$79,500
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R03AR049383-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R03AR049383-02
Patents
No Patents information available for 5R03AR049383-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R03AR049383-02
Clinical Studies
No Clinical Studies information available for 5R03AR049383-02
News and More
Related News Releases
No news release information available for 5R03AR049383-02
History
No Historical information available for 5R03AR049383-02
Similar Projects
No Similar Projects information available for 5R03AR049383-02